Explore All 2731 Add-on Acquisition Medical Products Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | April 21, 2011 |
| Target | Healthcare Brands International |
| Sector | Medical Products |
| Buyer(s) | Meda |
| Sellers(s) | EW Healthcare Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.8B SEK |
FILTER BY
Meda is an operator of an international specialty pharma company that is fully represented in Europe and the US through its own sales organizations in more than 50 countries. Meda’s products are sold in about 120 countries, and where it lacks a sales organization, it markets and sells its products via agents and other pharmaceutical companies. Meda has a diversified geographic footprint with approximately 62 percent of Meda's sales generated in Western Europe (the largest countries being Italy, Germany, France, and Sweden), 19 percent in Emerging Markets (driven by China, Russia, the Middle East, and Thailand) and 17 percent in the U.S. Meda has a network of seven manufacturing facilities in Europe, the U.S. and India. Meda is based in Solna, Sweden.
| Deal Context for Buyer | # |
|---|---|
| Overall | 5 of 7 |
| Sector: Medical Products | 1 of 1 |
| Type: Add-on Acquisition | 5 of 7 |
| Country: United Kingdom | 1 of 1 |
| Year: 2011 | 1 of 1 |
| Size (of disclosed) | 6 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-10-05 |
Alaven Pharmaceuticals
Marietta, Georgia, United States Alaven Pharmaceutical LLC is a specialty pharmaceutical company, develops and markets prescription and non-prescription products that treat women’s health, gastroenterology, and anemia conditions in the United States. |
Buy | $350M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-30 |
Acton Pharmaceuticals
Marlborough, Massachusetts, United States Acton Pharmaceuticals, Inc. is a US respiratory company. Its primary product is Aerospan. Aerospan is an inhaler for the treatment of asthma that contains the active substance Flunisolide. |
Buy | $135M |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1985 |
| PE ASSETS | 3.0B USD |
| Size | Large |
| Type | Sector Focused |
Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.
| Deal Context for Seller | # |
|---|---|
| Overall | 24 of 53 |
| Sector: Medical Products | 13 of 24 |
| Type: Add-on Acquisition | 15 of 34 |
| Country: United Kingdom | 1 of 1 |
| Year: 2011 | 2 of 5 |
| Size (of disclosed) | 12 of 22 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-04-18 |
Prism Pharmaceuticals
King of Prussia, Pennsylvania, United States Prism, located in King of Prussia, Pennsylvania, is a leading specialty pharmaceutical company committed to developing and commercializing acute care cardiovascular products. Prism is focused on recognizing unfulfilled opportunities in existing compounds that target acute care cardiovascular needs and comprehensively developing them to achieve their full market potential. |
Sell | $338M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-05-13 |
ProteinSimple
Santa Clara, California, United States ProteinSimple develops instrumentation systems, software and assay products that drive discoveries in fields ranging from fundamental protein research to biomarker discovery and personalized medicine. |
Buy | - |
